New therapies for pneumococcal meningitis

Cottagnoud, PH; Täuber, MG (2004). New therapies for pneumococcal meningitis. Expert opinion on investigational drugs, 13(4), pp. 393-401. London: Informa Healthcare 10.1517/13543784.13.4.393

Full text not available from this repository. (Request a copy)

The treatment of pneumococcal meningitis remains a major challenge, as reflected by the continued high morbidity and case fatality of the disease. The worldwide increase of penicillin-resistant pneumococci and more recently cephalosporin- and vancomycin-tolerant pneumococci has jeopardised the efficacy of standard treatments based on extended spectrum cephalosporins alone or in combination with vancomycin. This review provides a summary of newly developed antibiotics tested in the rabbit meningitis model. In particular, newer beta-lactam monotherapies (cefepime, meropenem, ertapenem), recently developed quinolones (garenoxacin, gemifloxacin, gatifloxacin, moxifloxacin) and a lipopeptide antibiotic (daptomycin) are discussed. A special emphasis is placed on the potential role of combination treatments with some of the new compounds, which are of interest based on the background of increasing resistance problems due to their often synergistic activity in the rabbit model of pneumococcal meningitis.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute for Infectious Diseases

UniBE Contributor:

Täuber, Martin G.

ISSN:

1354-3784

ISBN:

15102588

Publisher:

Informa Healthcare

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:00

Last Modified:

06 Dec 2013 13:50

Publisher DOI:

10.1517/13543784.13.4.393

PubMed ID:

15102588

Web of Science ID:

000220797300007

URI:

https://boris.unibe.ch/id/eprint/25719 (FactScience: 60804)

Actions (login required)

Edit item Edit item
Provide Feedback